HCPCS Level II code J0174 designates lecanemab-irmb, a monoclonal antibody product supplied for intravenous injection in 1 mg units. As an HCPCS Level II drug code, J0174 is the billing identifier used across outpatient infusion settings and hospital outpatient departments to record administration and drug supply. The code is nationally relevant given lecanemab's role in treating neurologic disease and the high-cost, high-utilization nature of infused biologics.

Key payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise briefing on clinical context, typical sites of service, and payer considerations for coverage and billing. The publication summarizes benchmark topics such as unit-based drug billing, common billing modifiers, and payer policy themes for infused biologics.

The report provides operational detail useful for revenue cycle, compliance, and clinical teams: what the HCPCS Level II code represents, where it is typically billed, and which major commercial and public payers are commonly involved. Data limitations are noted where source details were not supplied. The focus is national in scope and intended to inform payers, providers, and billing professionals about the billing identity and practical context of J0174.